ClinicalTrials.gg
CompletedNCT04753788LAMP4YAWSUpdated Mar 24, 2025Results posted

Evaluation of a LAMP Assay for T. Pallidum. Pertenue

An observational study in Yaws, sponsored by London School of Hygiene and Tropical Medicine. Completed at 3 sites in 3 countries. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by London School of Hygiene and Tropical Medicine · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
563
Sex
All
01

Study summary

This is a diagnostic evaluation comparing the performance of real-time PCR performed at a national reference laboratory and a LAMP assay performed at a regional hospital for the diagnosis of yaws

02

Conditions studied

  • Yaws
03

In context

Lead sponsor

London School of Hygiene and Tropical Medicine is the lead sponsor of 298 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with clinically suspected yaws lesions in Ghana, Cote d'Ivoire and Cameroon will be screened using the DPP Syphilis Screen and Confirm RDT. If positive samples will be taken for PCR and LAMP testing.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Lesion consistent with yaws
  • Positive treponemal and non-treponemal antibodies assessed by the DPP Syphilis Screen and Confirm RDT

Exclusion criteria

Exclusion Criteria:

  • Unable to give consent
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
563 participants (actual)
Patient registry
No

Groups and cohorts

  • Suspected Yaws Cases

    Individuals with a lesion clinically suspected to be yaws and with evidence of positive treponemal and non-treponemal serology as assessed by point of care lateral flow tests (DPP Syphilis Screen and Confirm, Chembio)

    Diagnostic Test: PCR · Diagnostic Test: LAMP

Interventions

  • Diagnostic testPCR

    qPCR for T.pallidum

  • Diagnostic testLAMP

    LAMP assay for T.pallidum

06

What researchers measure

Primary outcomes

  1. Sensitivity of LAMP vs qpCR

    A case of Yaws Positive for T.pallidum DNA by PCR that is also positive by LAMP

    Time frame: 15 Months

  2. Specificity of LAMP for Yaws

    Sample negative by qPCR for T.pallidum that is also negative by LAMP

    Time frame: 15 Months

07

Results

Posted Mar 24, 2025

Participant flow

Participant flow — Overall Study
MilestoneSuspected Yaws Cases
Started563
Completed525
Not completed38

Outcome measures

PrimarySensitivity of LAMP vs qpCR

A case of Yaws Positive for T.pallidum DNA by PCR that is also positive by LAMP

Time frame:
15 Months
Reported as:
Number · Percent
Sensitivity of LAMP vs qpCR
PercentSerologically Confirmed Yaws
Sensitivity of LAMP vs qpCR63.2 (60.6 to 70.9)
PrimarySpecificity of LAMP for Yaws

Sample negative by qPCR for T.pallidum that is also negative by LAMP

Time frame:
15 Months
Reported as:
Number · Percent
Specificity of LAMP for Yaws
PercentSerologically Confirmed Yaws
Specificity of LAMP for Yaws67.1 (61.6 to 72.8)

Adverse events

Collected over This is a diagnostic accuracy study without collection of data on AE/SAEs. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Suspected Yaws Cases———

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Suspected Yaws Cases
<=18 years525
Between 18 and 65 years0
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Suspected Yaws Cases
Female149
Male376
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Suspected Yaws Cases
Hispanic or Latino0
Not Hispanic or Latino525
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Suspected Yaws Cases
Cameroon20
Côte D'Ivoire93
Ghana408
Congo4
08

Study locations

3 sites
  • Centre Pasteur
    Yaoundé, Cameroon
  • Institut Pasteur
    Abidjan, Côte D'Ivoire
  • Noguchi Memorial Institute of Medical Research
    Accra, Ghana
09

References and documents

Publications

  • Handley BL, Gonzalez-Beiras C, Tchatchouang S, Basing LA, Hugues KA, Bakheit M, Becherer L, Ries C, Njih Tabah E, Crucitti T, Borst N, Luert S, Frischmann S, Haerpfer T, Landmann E, Amanor I, Sylla A, Kouame-Sina MS, Ndzomo-Ngono JP, Tano A, Arhinful D, Awondo P, Ngazoa Kakou S, Eyangoh S, Addo KK, Harding-Esch EM, Knauf S, Mitja O, Marks M. LAMP4yaws: Treponema pallidum, Haemophilus ducreyi loop mediated isothermal amplification - protocol for a cross-sectional, observational, diagnostic accuracy study. BMJ Open. 2022 Mar 29;12(3):e058605. doi: 10.1136/bmjopen-2021-058605. PubMed 35351731 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Sep 2023, 30 months.

Results were first posted in Mar 2025, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2021
First posted
Feb 15, 2021
StartActual
Mar 15, 2021
Primary completionActual
Sep 23, 2023
CompletionActual
Sep 30, 2024
Results first posted
Mar 24, 2025
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04753788
Collaborators
Pasteur Institute abidjan, Centre Pasteur du Cameroun, Noguchi Memorial Institute for Medical Research, University of Freiburg, MAST Group - Germany, Friedrich-Loeffler-Institut, Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Responsible party
Sponsor
First posted
Feb 15, 2021
Start date
Mar 15, 2021
Primary completion
Sep 23, 2023
Completion
Sep 30, 2024
Results posted
Mar 24, 2025
Last update
Mar 24, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion